<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04140253</url>
  </required_header>
  <id_info>
    <org_study_id>24012019</org_study_id>
    <nct_id>NCT04140253</nct_id>
  </id_info>
  <brief_title>Evaluation of Duloxetine and Innovative Pelvic Floor Muscle Training in Women With Stress Urinary Incontinence</brief_title>
  <acronym>DULOXING</acronym>
  <official_title>A Randomized-Intervention, Parallel, Multicentric Study to Evaluate Duloxetine and Innovative Pelvic Floor Muscle Training in Women With Uncomplicated Stress Urinary Incontinence - The DULOXING Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Comenius University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Comenius University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, tolerability and efficacy of duloxetine and pelvic floor
      muscle training in women who suffer from stress urinary incontinence
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized-intervention, parallel, multicentric study which will evaluate the
      safety, tolerability and efficacy of oral duloxetine and innovative pelvic floor muscle
      training to woman suffering from stress urinary incontinence
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2019</start_date>
  <completion_date type="Actual">March 10, 2020</completion_date>
  <primary_completion_date type="Actual">February 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in incontinence episode frequency</measure>
    <time_frame>over 12 weeks of treatment</time_frame>
    <description>The investigators will compare change in incontinence episode frequency in the combined duloxetine and pelvic floor muscle training to duloxetine treatment alone</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in incontinence quality of life according to Incontinence Quality of Life scale (I-QoL)</measure>
    <time_frame>over 12 weeks of treatment</time_frame>
    <description>The investigators will compare change in incontinence quality of life in the combined duloxetine and pelvic floor muscle training to duloxetine treatment alone. 0 = worst quality of life, 100 = best quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient Global Impression of Improvement (PGI-I score)</measure>
    <time_frame>over 12 weeks of treatment</time_frame>
    <description>To examine change in Patient Global Impression of Improvement in the combined duloxetine and pelvic floor muscle training to duloxetine treatment alone . 1 = much better. 7 = definitely worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>over 12 weeks of treatment</time_frame>
    <description>To examine incidence of adverse events in the combined duloxetine and pelvic floor muscle training to duloxetine treatment alone</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">158</enrollment>
  <condition>Stress Urinary Incontinence in Women</condition>
  <arm_group>
    <arm_group_label>Standard Duloxetine treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Peroral treatment with duloxetine at a dose of 40 mg twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Duloxetine treatment with PFMT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Peroral treatment with duloxetine at a dose of 40 mg twice a day. Pelvic floor muscle training (PFMT) with lumbopelvic stabilization.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Pelvic floor muscle training (PFMT) with lumbopelvic stabilization</intervention_name>
    <description>Pelvic floor muscle training (PFMT) with lumbopelvic stabilization.
Educating of probands about anatomy, physiology, and pelvic floor muscles functions
Training of pelvic floor muscles in different position
Training of pelvic floor muscles with lumbopelvic stabilization
Exercise 5 times a week for 20-30 minutes a day, after initial training with a physiotherapist.</description>
    <arm_group_label>Standard Duloxetine treatment</arm_group_label>
    <arm_group_label>Standard Duloxetine treatment with PFMT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Woman's willing to provide written informed consent

          -  Women over 18 years that experience uncomplicated stress urinary incontinence

          -  Score of the International Consultation on Urinary Incontinence Questionnaire ≥ 14
             points

          -  Symptoms of urinary incontinence for at least 3 consecutive months

          -  Have at least seven urinary incontinence episodes per week

          -  Degree of pelvic organ prolapse ≤ 2 stage

          -  Willingness to accept the randomization process and fully participate in tests

        Exclusion Criteria:

          -  Recent use of any pharmacologic agent used to treat symptoms of urinary incontinence
             in the past six months

          -  History of anti-incontinence surgery in the past 12 months

          -  Use of onabotulinumtoxinA for the treatment of urinary incontinence in the past 12
             months

          -  History of pelvic prolapse repair or urethral surgery in the past 12 months

          -  History of pelvic floor muscle training in the past 12 months

          -  History of interstitial cystitis or bladder-related pain

          -  Chronic severe constipation

          -  Clinically significant renal or hepatic impairment

          -  Clinically significant heart impairment

          -  Pregnant woman, lactating, or actively trying to become pregnant

          -  Non-compliance with limitation of duloxetine treatment for mixed urinary incontinence

          -  Positive urinary tract infection

          -  Use of rehabilitation aids (pessary, urethral plugs, vaginal beads, etc.)

          -  Use of antidepressant therapy

          -  Insufficient understanding of pelvic floor exercises and/or omitting exercises

          -  Participation in any clinical study in the past six months
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>woman with stress urinary incontinence</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava</name>
      <address>
        <city>Martin</city>
        <zip>03601</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Slovakia</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 22, 2019</study_first_submitted>
  <study_first_submitted_qc>October 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2019</study_first_posted>
  <last_update_submitted>July 18, 2020</last_update_submitted>
  <last_update_submitted_qc>July 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stress urinary incontinence</keyword>
  <keyword>Pelvic floor muscle training</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Urinary Incontinence, Stress</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>After study completion</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

